BioCentury | Oct 31, 2019
Company News

Roivant pockets $3B from Dainippon, reveals CF focus of fifth ‘vant’

As Roivant cements its deal for Dainippon to acquire five of its “vants” for $3 billion, the biotech revealed the identity of the deal’s fifth subsidiary, which will develop gene therapies for cystic fibrosis. Sumitomo...
BioCentury | Apr 20, 2017
Product R&D

Stalling translation

...drugs that produces fewer hits than genotypic screening, but where the hits are more relevant. Spiros...
...outcome to be able to stall less than 20 proteins out of the entire proteome.” Spiros...
BioCentury | Sep 12, 2016
Politics, Policy & Law

Executive power

Years of congressional gridlock have caused power in Washington to shift to the White House, making the levers of power less accessible to pharmaceutical industry lobbyists. While Congress will continue to mine outrage over drug...
BioCentury | Aug 21, 2014
Tools & Techniques

Circling back to basics

...an assistant professor of chemistry at Tufts University who led one of the three studies. Spiros...
BioCentury | Jul 21, 2014
Product Development

Seamless solution in AML

In an effort to overcome recruiting challenges for elderly patients with acute myelogenous leukemia, Cyclacel Pharmaceuticals Inc. and FDA agreed on a SPA for a registrational Phase III study that incentivizes enrollment with an active...
BioCentury | Feb 24, 2014
Product Development

Dosing certainty

...from placebo up to the highest dose. This gives greater efficiency and certainty," said Hemmings. Spiros...
BioCentury | Nov 15, 2012
Cover Story

Bringing macrocycles full circle

...neatly into either conventional academic research or the corporate world. According to think tank member Spiros...
BioCentury | Sep 17, 2012
Product Development

Excited about cycling

...the clinic that will be the critical next step for the field," he told BioCentury. Spiros...
BioCentury | Aug 22, 2012
Clinical News

BioCentury, Nature Publishing Group announce SciBx summit

...free. Please register here . The scheduled speakers are: Bruce Booth, partner at Atlas Venture; Spiros...
BioCentury | Jun 9, 2011
Cover Story

Raising a Treg cell army

...on how to generate and potentially manipulate T reg cells toward being whole-cell therapies," said Spiros...
Items per page:
1 - 10 of 103
BioCentury | Oct 31, 2019
Company News

Roivant pockets $3B from Dainippon, reveals CF focus of fifth ‘vant’

As Roivant cements its deal for Dainippon to acquire five of its “vants” for $3 billion, the biotech revealed the identity of the deal’s fifth subsidiary, which will develop gene therapies for cystic fibrosis. Sumitomo...
BioCentury | Apr 20, 2017
Product R&D

Stalling translation

...drugs that produces fewer hits than genotypic screening, but where the hits are more relevant. Spiros...
...outcome to be able to stall less than 20 proteins out of the entire proteome.” Spiros...
BioCentury | Sep 12, 2016
Politics, Policy & Law

Executive power

Years of congressional gridlock have caused power in Washington to shift to the White House, making the levers of power less accessible to pharmaceutical industry lobbyists. While Congress will continue to mine outrage over drug...
BioCentury | Aug 21, 2014
Tools & Techniques

Circling back to basics

...an assistant professor of chemistry at Tufts University who led one of the three studies. Spiros...
BioCentury | Jul 21, 2014
Product Development

Seamless solution in AML

In an effort to overcome recruiting challenges for elderly patients with acute myelogenous leukemia, Cyclacel Pharmaceuticals Inc. and FDA agreed on a SPA for a registrational Phase III study that incentivizes enrollment with an active...
BioCentury | Feb 24, 2014
Product Development

Dosing certainty

...from placebo up to the highest dose. This gives greater efficiency and certainty," said Hemmings. Spiros...
BioCentury | Nov 15, 2012
Cover Story

Bringing macrocycles full circle

...neatly into either conventional academic research or the corporate world. According to think tank member Spiros...
BioCentury | Sep 17, 2012
Product Development

Excited about cycling

...the clinic that will be the critical next step for the field," he told BioCentury. Spiros...
BioCentury | Aug 22, 2012
Clinical News

BioCentury, Nature Publishing Group announce SciBx summit

...free. Please register here . The scheduled speakers are: Bruce Booth, partner at Atlas Venture; Spiros...
BioCentury | Jun 9, 2011
Cover Story

Raising a Treg cell army

...on how to generate and potentially manipulate T reg cells toward being whole-cell therapies," said Spiros...
Items per page:
1 - 10 of 103